Clinical Trials

Last Updated: 11/9/09

Leukemia Clinical Trials are Grouped by Disease Type:

• Phase I Agents
• Acute Lymphoblastic Leukemia 
• Acute Myelogenous Leukemia
• Myelodysplastic Syndromes 
• Chronic Lymphocytic Leukemia
• Chronic Myelogenous Leukemia
• Myeloproliferative Diseases

Phase I Agents

• HuM195/rGel (AML,MDS,CML) (DM98-342)
• BAY-43-9006 (ALL, AML, MDS, CML) (2004-0702)
• Clofarabine + Cytoxan (ALL) (2005-0552)
• 5 AZA-2 Deoxycytidine (ALL) (2005-0895)
• AT9283 (CML, MDS, MPD) (2006-0177)
• Gimatecan (MDS) (2006-0943)
• FAO (AML, MDS) (2006-1089)
• Oral Azacitidine (AML, MDS) (2007-0405)
• RO5045337 (ALL, AML, CLL, CML) (2007-0408)
• OPB-31121 (ALL, AML, MDS, CLL, CML) (2007-0488)
• Bendamustine (ALL, AML, MDS, CML) (2007-0634)
• SB 939 (ALL, AML, MDS) (2007-0848)
• ARRY-520 (AML, MDS, CML) (2007-0879)
• SB1518 (AML, MDS, CML, MPD) (2008-0032)
• AP24534 (2008-0046)
• JNJ-26481585 (MDS) (2008-0245)
• DT2219ARL (ALL) (2008-0519)
• DCC-2036 (ALL, CML) (2008-0732)
• IMC-EB10 (AML) (2009-0042)
• PMA112509 (AML, MDS) (2009-0046)
• ORAL ARRY-614 (MDS) (2009-0129)
• AZD1152 + Ara-C (AML) (2009-0172)
• SAR103168 (AML) (2009-0196)
• GSK1120212 (ALL, AML, MDS, CLL, CML) (2009-0239)
• DAC (MDS) (2009-0286)

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated 

• Hyper-CVAD + Dasatinib (2006-0478)
• Hyper-CVAD + Rituximab (ID02-229)
• Modified Hyper-CVAD +/- Rituximab  (ID02-230)
• Hyper-CVAD + Nelarabine (2006-0328)

Salvage Programs

• Hyper-CVAD + Dasatinib (2006-0478)
• SKI-606 (2005-0813)
• Dasatinib (2007-0606)
• PHA-739358 (2007-0939)
• ap24534 (2008-0046)
• DCC-2036 (2008-0732)
• DT2219ARL (ALL) (2008-0519)
• Clofarabine + Cytoxan (2005-0552)
• 5 AZA-2 Deoxycytidine (2005-0895)
• INCB018424 (2007-0925)
• MOAD (2008-0267)
• Mek Inhibitor AS703026 (2009-0195)

Supportive Care

• Actonel vs. Placebo for Prevention of Bone Loss (ID03-0124)
• White Blood Cell Transfusion (2007-0797)

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

• Fludarabine, Ara-C, G-CSF and Gemtuzumab Ozogamicin (2007-0147)
• ATRA and arsenic +/- gemtuzumab and theophylline (2006-0706)
• Ida + Ara-C + SAHA (2007-0835)
• Ida + Ara-C + Sorafenib (2006-0977)
• Ida + Ara-C (2006-0813)
• DAC + Gemtuzumab Ozogamicin (2008-0288)
• Vorinostat + Aza (2007-0685)
• Clofarabine + Ara-C + DAC (2007-0039)
• DAC +/- Valproic Acid (2006-0686)
• Oral Sapacitabine (2007-0727)
• DAC + Mylotarg (2008-0288)
• SNS-595 (2007-0965)
• Bendamustine (2007-0634)
• CPX-351 vs 3+7 (2008-0603)
• AZD1152 + Ara-C (2009-0172)
• AZD1152 vs low dose Ara-C (2009-0217)
• Mek Inhibitor AS703026 (2009-0195)
• Vorinostat + Aza (2007-0685)
• GSK1120212 (2009-0239)
• Randomized study of DAC vs observation as maintenance therapy (2006-0358)

Salvage

• Oral Tamibarotene (2007-0512)
• Oral Sapacitabine (2007-0727)
• DAC + Gemtuzumab Ozogamicin (2008-0288)
• CPX vs standard salvage therapy (2008-0679)
• Revlimid (2006-0293)
• INCB018424 (2007-0925)
• ly2181308 (2007-0707)
• DT388IL3 (2008-0313)
• PMA112509 (2009-0046)
• FAO (2006-1089)
• Voreloxin + Ara-C (2009-0131)
• Randomized Clofarabine + Ara-C vs Ara-C (2006-0069)
• SAR103168 (2009-0196)
• Bendamustine (2007-0634)
• Mek Inhibitor AS703026 (2009-0195)

Myelodysplastic Syndrome (MDS) (Includes CMML)

• ORAL ARRY-614 (MDS) (2009-0129)
• LBH 589 (2007-0713)
• DACOGEN (Decitabine) (2007-0883)
• JNJ-26481585 (2008-0245)
• Revlimid + Darbepoetin alfa (2006-0657)
• Oral Azacitidine (2007-0405)

IPSS Int-1

• ORAL ARRY-614 (MDS) (2009-0129)
• LBH 589 (2007-0713)
• DACOGEN (Decitabine) (2007-0883)
• JNJ-26481585 (2008-0245)
• LD DAC +/- VA (2006-0686)
• Oral Clofarabine (2005-0536)
• Oral Azacitidine (2007-0405)
• Gimatecan (2006-0943)

IPSS int-2 or high

• LD DAC +/- VA (2006-0686)
• Oral Sapacitabine (2007-0727)
• Oral Clofarabine (2005-0536)
• Clofarabine + Ara-C + DAC (2007-0039)
• SB 939 (2007-0848)
• JNJ-26481585 (2008-0245)
• INCB018424 (2007-0925)
• DAC + Gemtuzumab Ozogamicin (2008-0288)
• Ida + Ara-C + Sorafenib (2006-0977)
• DT388IL3 (2008-0313)
• Gimatecan (2006-0943)
• PMA112509 (2009-0046)
• Oral Azacitidine (2007-0405)

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - all stages 

• FCR (2008-0431)
• Lenalidomide (2008-0385)

Mimimal Residual Disease 

• Rituximab + Alemtuzumab (2006-0767)

Prior Therapy

• FCR + Bevacizumab (2005-0992)
• HuMax-CD20 (2006-0314)
• OFAR 2 (2006-1026)
• ABT-263 (2007-0096)
• GS9219 (2007-0087)
• 8-Cloro-Adenosine (2004-0144)
• Dasatinib (BMS-354825) (2005-0497)
• 5-Aza (2006-0428)
• AMD3100 (2008-0725)
• FAMP + CTX + Rituxan (ID99-338)
• Alemtuzumab (2007-0626)
• RO5045337 (2007-0408)
• Milatuzumab (hLL1) (2008-0075)

Other Studies

• 2CDA + Rituximab in Hairy Cell Leukemia (2004-0223)
• Kinetic Biomarker (2005-0528)

Chronic Myelogenous Leukemia (CML)

Chronic phase

• BMS-354825 (2005-0422)
• Oral AMN107 (2005-0048)
• AP24534 (2008-0046)
• DCC-2036 (2008-0732)
• PHA-739358 (2007-0939)
• INCB018424 (2007-0925)

Accelerated Phase

• AP24534 (2008-0046)
• DCC-2036 (2008-0732)
• PHA-739358 (2007-0939)
• INCB018424 (2007-0925)
• SB1518 (2008-0032)

Blastic Phase

• PHA-739358 (2007-0939)
• AP24534 (2008-0046)
• DCC-2036 (2008-0732)
• INCB018424 (2007-0925)
• SB1518 (2008-0032)

Imatinib failures with T315l mutations (any stage)

• AP24534 (2008-0046)
• DCC-2036 (2008-0732)
• Homoharringtonine (CGX0635) (2006-0192)
• PHA-739358 (2007-0939)
• INCB018424 (2007-0925)

Minimal Residual Disease

• Dasatinib + Ipilimumab (2008-0157)

Myeloproliferative Diseases

• INCB018424 (CIMF) (2008-0874)
• Pomalidomide (CC-4047) (CIMF) (2007-0199
• INCB018424-251 - JAK2 Oral (CIMF) (2007-0169)
• Bevacizumab (CIMF) (2008-0025)
• TG101348 (CIMF) (2007-0837)
• Long term effects of TF101348 (CIMF) (2008-0421)
• AZD1480 (CIMF) (2009-0067)
• SB1518 (CIMF) (2008-0032)
• Mek Inhibitor AS703026 (CIMF) (2009-0195)
• PEG IFN-alpha2a (PV, ET) (DM03-0109)
• 2CDA + Ara-C (HES) (DM97-232)
• Evaluation of Obatoclax Mesylate (SM) (2008-0792)
• Masitinib vs Placebo (SM) (2008-0275)